Peptidomimetic macrocycles

1. A method of treating neutropenia, thrombocytopenia, or anemia in a subject, the method comprising administering an effective amount of a peptidomimetic macrocycle to the subject, wherein the peptidomimetic macrocycle comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 760.

2. The method of claim 1 , wherein the peptidomimetic macrocycle comprises an amino acid sequence which is at least 90% identical to SEQ ID NO: 760.

3. The method of claim 1 , wherein the peptidomimetic macrocycle comprises an amino acid sequence which is SEQ ID NO: 760.

4. The method of claim 1 , wherein the peptidomimetic macrocycle has the formula:

wherein:

each A, C, D, and E is independently a natural or non-natural amino acid, and each D or E independently optionally includes a capping group;

each B is independently a natural or non-natural amino acid, amino acid analog, or

each R 1 and R 2 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;

each R 3 is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 ;

each L is independently a macrocycle-forming linker of the formula -L 1 -L 2 -;

each L 1 and L 2 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [—R 4 —K—R 4 —] n , each optionally substituted with R 5 ;

each R 4 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ;

each R 5 is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent;

each R 6 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R 7 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, each optionally substituted with R 5 , or forms part of a cyclic structure with a D residue;

each R 8 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, each optionally substituted with R 5 , or forms part of a cyclic structure with an E residue;

each v and w is independently an integer from 1-1000;

u is an integer from 1-10;

each x, y and z is independently an integer from 0-10; and

each n is independently an integer from 1-5.

5. The method of claim 4 , wherein D comprises the capping group.

6. The method of claim 4 , wherein E comprises the capping group.

7. The method of claim 6 , wherein the capping group comprises an amino group.

8. The method of claim 4 , wherein the peptidomimetic macrocycle comprises an α-helix.

9. The method of claim 4 , wherein the peptidomimetic macrocycle comprises an α,α-disubstituted amino acid.

10. The method of claim 4 , wherein L 1 and L 2 are independently C 3 -C 6 alkenylene.

11. The method of claim 4 , wherein R 1 and R 2 are methyl.